LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

81.8 -2.94

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

81.06

Max

84.41

Galvenie mērījumi
By Trading Economics
Ienākumi	-252M -129M
Pārdošana	-295M 157M
Peļņas marža	-82.062
Darbinieki	1,069
EBITDA	-254M -103M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+14.66% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 25. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	2.1B 14B
Iepriekšējā atvēršanas cena	84.74
Iepriekšējā slēgšanas cena	81.8

Ziņu noskaņojums

By Acuity

58%

42%

297 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. febr. 23:57 UTC

Karstas akcijas

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

2026. g. 12. febr. 23:35 UTC

Peļņas

Galvenie tirgus virzītāji

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

2026. g. 12. febr. 23:28 UTC

Peļņas

Applied Materials Profit Rises on Soaring AI Demand -- Update

2026. g. 12. febr. 21:47 UTC

Peļņas

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

2026. g. 13. febr. 00:00 UTC

Tirgus saruna

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

2026. g. 12. febr. 23:47 UTC

Tirgus saruna

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

2026. g. 12. febr. 23:38 UTC

Tirgus saruna

Gold Steady; Could Undergo Technical Recovery -- Market Talk

2026. g. 12. febr. 23:33 UTC

Peļņas

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

2026. g. 12. febr. 23:09 UTC

Tirgus saruna

South32's Hermosa Review Stokes Spending Fears -- Market Talk

2026. g. 12. febr. 22:55 UTC

Peļņas

Karstas akcijas

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

2026. g. 12. febr. 22:46 UTC

Tirgus saruna

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

2026. g. 12. febr. 22:23 UTC

Peļņas

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

2026. g. 12. febr. 22:15 UTC

Peļņas

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

2026. g. 12. febr. 22:15 UTC

Peļņas

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

2026. g. 12. febr. 22:15 UTC

Peļņas

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

2026. g. 12. febr. 22:15 UTC

Peļņas

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

2026. g. 12. febr. 22:00 UTC

Peļņas

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026. g. 12. febr. 22:00 UTC

Peļņas

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

2026. g. 12. febr. 22:00 UTC

Peļņas

Agnico-Eagle Mines 4Q Net $1.52B >AEM

2026. g. 12. febr. 22:00 UTC

Peļņas

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

2026. g. 12. febr. 22:00 UTC

Peļņas

2026. g. 12. febr. 22:00 UTC

Peļņas

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

2026. g. 12. febr. 21:57 UTC

Peļņas

XP 4Q Rev BRL4.95B >XP

2026. g. 12. febr. 21:52 UTC

Peļņas

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026. g. 12. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 12. febr. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 12. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 12. febr. 21:47 UTC

Peļņas

Morningstar 4Q Rev $641M >MORN

2026. g. 12. febr. 21:39 UTC

Peļņas

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026. g. 12. febr. 21:38 UTC

Peļņas

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

14.66% augšup

Prognoze 12 mēnešiem

Vidējais 97.22 USD 14.66%

Augstākais 110 USD

Zemākais 87 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

297 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.